15th Pharmacovigilance 2018 Business

The entire program will cover the detection, analysis and prevention of adverse drug reactions. It will be studied with the help of case st

15th Pharmacovigilance 2018
21st & 22nd February 2018, Holiday Inn, Kensington High Street, London UK
“Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management”

15th Annual Pharmacovigilance 2018 will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. The entire program will cover the detection, analysis and prevention of adverse drug reactions. It will be studied with the help of case studies and industry experiences. This conference will help the drug safety representatives from the pharmaceutical industry and quality research organisations who wish to understand how to avoid common deficiencies in inspections by learning from the experiences of others to gain a greater understanding of new and existing pharmacovigilance requirements, and to improve their organisation’s compliance with pharmacovigilance requirements.
KEY SPEAKERS:
• VICKI R EDWARDS, Vice President, Pharmacovigilance Excellence and QPPV, Abbvie
• KARSTEN LOLLIKE, Corporate Vice President and QPPV, Novo Nordisk
• KHAUDEJA BANO, Senior Medical Director Medical Affairs, Abbott (USA)
• RENE HALTINER, Managing Director / Senior PV Strategy Lead, Conceptual Process Solutions / F. Hoffmann-La Roche
• JOHN SOLOMON, Head of Pharmacovigilance - UK & Ireland, Sanofi
• YUUNG YUUNG YAP, Senior International Regulatory Counsel, EU and International Regulatory Law, Pfizer
• DAVID J LEWIS, Senior Adviser Pharmacovigilance, Novartis
• TANJA PETERS, Global Head of PV Intelligence, Deputy EU QPPV, Boehringer Ingelheim
• MICHAEL BEAN, Senior Director, Regulatory Compliance R&D, Janssen Pharmaceutical
• SUSAN WELSH, Chief Safety Officer, CSL Behring (USA)
• HELEN MCASKILL, Interim Head of Research and Development at Department of Health, Isle of Man Government
• FRANCK SCHWARTZ, QA Global Inspection, Intelligence Lead - Compliance and Regulatory Affairs, Novartis
• RICARDA TIEMEYER, Head of Drug Safety & PoC Medical Information, Roche
• MICHAEL RICHARDSON, VP International GPV&E and EU QPPV, Bristol-Myers Squibb
• RUDI SCHEERLINCK, Head Global Drug Safety, Basilea Pharmaceuticals
• SUMIT MUNJAL, Global Director, Pharmacovigilance & EU Region Medical Advisor - Lead Oncology Portfolio, Takeda Pharmaceuticals
• MICK FOY, Group Manager, Vigilance Intelligence and Research Group Vigilance and Risk Management, MHRA
• ULRICH VOGEL, Head Strategic Data Analysis, Global Pharmacovigilance, Boehringer Ingelheim
• JACKIE ROBERTS, Executive Director Regulatory, Pharmacovigilance and Medical, Accord Healthcare
• STEINAR MADSEN, Medical Director, Norweigen Medicines Agency
• PHILIP EICHORN, Senior Director (Worldwide Safety and Regulatory), Pfizer
• HEINZ WEIDENTHALER, Director Pharmacovigilance, QPPV, Bavarian Nordic
• KATHRIN WAWRA-HEHENBERGER, Director, Clinical Safety Physician, CSL Behring
• MIRCEA CIUCA, Global Head Medical & Clinical Drug Safety, Vifor Pharma
• KAREN CHENG, Safety Risk Lead, Pfizer
• MODESTAS JARUTIS, Medical Manager, Roche
• G. NARAYANAN, Vice President, Disruptive Biologics, Voisin Consulting Life Sciences
• JORGE GONZALEZ BORROTO, Pharmacovigilance Officer / Nonclinical Toxicology Expert, Ferrer Internacional
• ANDREA MAULWURF, Head of Pharmacovigilance, EU-QPPV, Allergy Therapeutics
• DAVID JEFFERYS, Sr. VP Regulatory, Eisai
• CHETAN SHATAPATHY, Director, Sanjeevani Pharma
• SANDY EISEN, Chief Medical Officer, Frontline Pharma Consulting
• HILARY JONES, Of Counsel, Bristows
Plus many more
KEY THEMES:
• Pharmacovigilance in 2020 - future horizons and efficiencies
• Updates towards of legislation, policies, systems, technology, communication strategies and best practice in PV
• Possible effects of Brexit on Pharmacovigilance
• Strategies for best practice in bene t-risk management
• Market analysis – What is our current stand? – Moving towards the new successful PV era
• Implementing risk minimization procedures - Making sure we succeed
• Examining developments in GVP measures and status of the new Module VI
• Improving in signal management and their implications
• Safety information
• Medical devices
• Good Clinical Practices and Good Pharmacovigilance practices
• IT and new technologies for improvement of PV and clinical research
• Maintaining proper balance in relationships: Sponsor – Site – CRO & Patients
• Patient centric approach to help improve patient safety
• Outsourcing activities
• PV Audit & inspections
• Discover approaches for collecting, integrating and analyzing all of the safety data generated from preclinical models
• Accelerating new medicine introduction in developing world & overcoming challenges
WHO SHOULD ATTEND:-
CEO’s, CTO’s, CIO’s, Presidents, VPs, Directors, Heads, Managers, Scientific Advisors, Consultants of:
Pharmacovigilance , Pharmacoepidemiology, Pharmacogenomics, Drug/Product Safety, Drug Development, Information and Clinical Data Management, Clinical Pharmacology, Clinical Safety, Periodical safety update Reports, Risk Management, Research & Development, Quality Assurance, Patient Safety, Signal Detection, Safety Surveillance, Outcomes Research, Data Analysis, Epidemiology, Medical Affairs, Regulatory Affairs and Compliance, Information technology, Sales, and Marketing
CONFERENCE BOOKING DETAILS:
E-mail: [email protected] or TEL: +44 2036120886
Introductory Offer: 3 delegate places for the price of 2
Super Early Discount (until 08th December 2017): (£750 + VAT per delegate)
Standard Registration: (£1150 + VAT per delegate)
Conference Sponsor & Exhibition Stall and paid Speaker Slots are also available.

15th Pharmacovigilance conference will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting pharmacovigilance development.

More details